Phase-IIIb study results indicate Lyxumia—which is approved abroad but not in the US—was "non-inferior" in terms of controlling blood sugar levels regardless of whether the shot was given before breakfast or later.
Novo's global diabetes study finds that only 29% of polled patients were asked what they thought about prescribed regimens.
Sanofi top-lined positive clinical data today from its investigational basal insulin, as it seeks to defend its position in this fast-growing segment.
The drug maker's vision for 2014: fighting to keep Victoza top-of-mind with a US field force of around 3,000.
Researchers think a two-hormone approach could help control diabetes and obesity.
Researchers say the drug class could be linked to a lower autoimmune risk among diabetics.
The company says it is moving its Januvia sales pitch from defending market share to expanding it.
Amid talk of cost containment, Lilly said it's also enjoying nice returns from some of its older diabetes drugs.
The drug maker is giving its inhaled insulin another go.
Three former workers are accused of giving proprietary data to a drug company abroad.
The company it putting close to $4 billion towards developing pills that can replace insulin injections.
The CEO says Sanofi's patent-loss turnaround is coming.
Echoing a strategy similar to that posed by Merck, the drug maker told investors that its strategy for hitting revenue targets includes efficiencies. It also depends on a regulatory-friendly pipeline.
The company will "fill the bag" of its sales reps, as part of a reorganization that also includes 8,500 job cuts and a more refined R&D focus.
The diabetes-cholesterol combo is no more.
The company has partnered with Univision on a dance competition that supports health and weight loss. The segment, called Ritmo Dieta, will run for 13 weeks on the variety program Sábado Gigante.
Sanofi pulls GLP-1 diabetes med from FDA review; Gilead files oncology drug; BI/Lilly reveals results of head-to-head trial of its SGLT2 inhibitor vs. Januvia; BI campaign animates heartburn market; Girl Scouts take on mental health
Researchers say a two-year study shows the DPP-IV drug is not linked to a higher cardiovascular risk.
Eli Lilly is accused of misconduct in China, Health and Human Services tries to get young adults interested in health insurance, Novo kid-friendly insulin pen approved; India biotech says its Herceptin biosimilar will launch this year.
Phase III data for MannKind's Afrezza is positive, but past experience shows inhaled insulin may not be an immediate win.
Data show doctors are increasingly leaning on Regeneron's Eylea over Roche's Lucentis, as the two battle for share of the wet-AMD market.
Novo redoubled its Victoza marketing efforts after a recent setback, and that's made things tougher for GLP-1 rivals Bristol-Myers Squibb and AstraZeneca.
Proteus Digital Health's ingestible sensor shows utility as an adherence tool for those on psych meds, a study suggests.
GSK sees a regulatory setback on its once-weekly GLP-1 med, and Spectrum Pharma gets hit with an untitled letter from OPDP on a sales aid for Zevalin.
A report indicates that the FDA is siding with the European Medicines Agency's finding that GLP-1 diabetes medications are not conclusively linked to pancreatic cancer.
Quarterly sales fell 11% compared to the same period last year. The company plans on weathering a continued flow of patent losses with a narrower R&D focus.
Sales slid 9% during the second quarter, with generic Avapro and Plavix inflicting financial pain. The company says it is going to invest more to promote Eliquis among HCPs and plans on deploying a wider diabetes sales force.
The Indiana drug maker logged a 6% sales increase over the same period last year. Higher prices were responsible for the majority of the growth.
Three studies take on different angles of the patient experience. Spoiler alert: no cost increases are mentioned.
A Data and Safety Monitoring Board recommendation has wiped aleglitazar from the drug maker's slate of possible diabetes medications.